Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global ...
Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from ...
Also Announces Marketing Program VANCOUVER, BC / ACCESS Newswire / June 2, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") announces, ...
ACT Brief: Clinical Development Orchestration, Career Insights in Trials, and FDA Communication Gaps
In today's ACT Brief, we examine how program-level orchestration is becoming critical to R&D success, reflections on ...
Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) Achieved target ...
Why does it take a new drug 10 years, on average, to come to market? Part of the reason lies in the dead time in the process. Historically, trials have required tedious tabulations and repeated ...
The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin ...
Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials. In April, FDA announced plans for a pilot program to allow for real-time data review ...
Zacks Investment Research on MSN
FULC stock crashes as cancer risk forces its only drug program's end
Fulcrum Therapeutics FULC saw its stock crash 51.1% on Tuesday after announcing the discontinuation of its lead candidate, ...
Charitharth Vivek Lal, M.D. is program director of the Golden Week Program™, an evidence-based, standardized, quality improvement plan, established and implemented at the UAB Regional Neonatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results